Ferrostatin-1

SKU: orb1300714

Description

Ferrostatin-1

Research Area

Cell Biology, Infectious Disease & Virology

Key Properties

• CAS Number: 347174-05-4
• MW: 262.35
• Purity: 99.51%
• Formula: C₁₅H₂₂N₂O₂
• SMILES: CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1
• Target: Antifungal,Ferroptosis
• Solubility: Ethanol:26.2 mg/mL (99.87 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:20 mg/mL (76.23 mM);DMSO:237.5 mg/mL (905.28 mM)

Bioactivity

• Target IC50:
  HT22 cells:81.2 nM (EC50)|RAW 264. Cells:0.04 μM (EC50)|IMR-32 cells:18 nM|Ferroptosis:60 nM (EC50, HT-1080 cells)|Lymphocyte:48 nM (EC50)|LLC-MK2 cells:> 240 μM|Fibroblast:33 nM (EC50)|HT1080 cells:95 nM|NIH3T3 cells:0.22 μM
• In Vivo:
  METHODS: To investigate whether iron death is associated with LPS-induced acute kidney injury (AKI), Ferrostatin-1 (5 mg/kg) was administered intraperitoneally in a single dose to C57B-/- mice, and infectious AKI was induced by intraperitoneal injection of LPS (10 mg/kg) 30 min later. Results: Ferrostatin-1 significantly protected mice from renal dysfunction and tubular injury in LPS-induced AKI. METHODS: To investigate whether iron disorders are associated with acute liver disease and its molecular mechanism, Ferrostatin-1 (2.5 μM/kg) was intraperitoneally injected into ICR mice once a day for three days, followed by intraperitoneal injection of TAA (25 mg/kg/day) for three consecutive days, to establish an acute liver injury (ALI) model in mice. Results: Ferrostatin-1 pretreatment significantly reduced TAA-induced Changes in plasma ALT, AST and LDH levels, inhibite the expression of TfR1, Fpn and Ft-L proteins, and decreased iron accumulation without affectin the expression of xCT or GPX4 in the liver. Ferrostatin-1 prevents hepatic iron by decreasing death.
• In Vitro:
  METHODS: Human bronchial epithelial cells BEAS-2B were co-treated with LPS (10 mg/L) and Ferrostatin-1 (2 μM) for 16 h the growth Inhibition o the cells was detected by CCK-8 method. RESULTS: Ferrostatin-1 attenuate the LPS-induced cell damage. METHODS: Human fibrosarcoma cells HT-1080 were treated with Ferrostatin-1 (0.5 μM) and Erastin (10 μM) for 4 h, and ROS levels produced b the cells were measured by Flow Cytometry. Results: Ferrostatin-1 inhibite the Erastin-induced accumulation of cytoplasmic and lipid ROS. METHODS: Mouse hippocampal neuronal cells HT-22 were treated with Ferrostatin-1 (3-12 μM) for 16 h, then treated with 5 mM glutamate for 24 h, and then LDH release was measured. Results the release of LDH was significantly increased by treatment with glutamate, an the release of LDH was inhibited by Ferrostatin-1 treatment.
• Cell Research:
  Cell viability was typically assessed in 384-well format by Alamar Blue fluorescence (ex/em 530/590) measured on a Victor3 plate reader. In some experiments, Trypan Blue dye exclusion counting was performed using an automated cell counter. Cell viability under test conditions is reported as a percentage relative to the negative control treatment.

Storage & Handling

• Storage: keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Fungal, Fer 1, Fer1, Fer-1, Ferroptosis, Ferrostatin 1, Ferrostatin1, Ferrostatin-1, Ferrostatin-1 (Fer-1), Inhibitor, neurotoxicity, inhibit, cytosolic, death, cell, antifungal, antioxidant, ROS

Compound Identifiers

PubChem CID

4068248